HC Wainwright Brokers Raise Earnings Estimates for CRGX

CARGO Therapeutics, Inc. (NASDAQ:CRGX) – Investment analysts at HC Wainwright increased their Q1 2025 EPS estimates for shares of CARGO Therapeutics in a research report issued on Thursday, January 30th. HC Wainwright analyst R. Burns now anticipates that the company will earn ($0.61) per share for the quarter, up from their prior estimate of ($0.97). HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for CARGO Therapeutics’ current full-year earnings is ($3.74) per share. HC Wainwright also issued estimates for CARGO Therapeutics’ Q2 2025 earnings at ($0.47) EPS, Q3 2025 earnings at ($0.48) EPS, Q4 2025 earnings at ($0.50) EPS and FY2025 earnings at ($2.06) EPS.

Other analysts have also recently issued reports about the stock. Chardan Capital cut shares of CARGO Therapeutics from a “buy” rating to a “neutral” rating in a research note on Thursday, January 30th. William Blair cut shares of CARGO Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Thursday, January 30th. Truist Financial cut shares of CARGO Therapeutics from a “buy” rating to a “hold” rating and lowered their target price for the stock from $32.00 to $7.00 in a research note on Thursday, January 30th. Jefferies Financial Group cut shares of CARGO Therapeutics from a “buy” rating to a “hold” rating and lowered their target price for the stock from $32.00 to $3.00 in a research note on Thursday, January 30th. Finally, JPMorgan Chase & Co. cut shares of CARGO Therapeutics from an “overweight” rating to an “underweight” rating in a research report on Thursday, January 30th. One analyst has rated the stock with a sell rating and six have issued a hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $15.00.

CARGO Therapeutics Price Performance

NASDAQ CRGX opened at $3.70 on Monday. CARGO Therapeutics has a 1 year low of $3.00 and a 1 year high of $33.92. The stock has a market capitalization of $170.31 million, a PE ratio of -0.87 and a beta of 2.12. The company’s 50 day simple moving average is $14.02 and its two-hundred day simple moving average is $17.12.

CARGO Therapeutics (NASDAQ:CRGX) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.88) EPS for the quarter, beating analysts’ consensus estimates of ($1.14) by $0.26.

Hedge Funds Weigh In On CARGO Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Brooklyn Investment Group bought a new position in shares of CARGO Therapeutics during the 4th quarter valued at $27,000. China Universal Asset Management Co. Ltd. bought a new position in shares of CARGO Therapeutics during the 4th quarter valued at $141,000. BNP Paribas Financial Markets grew its holdings in shares of CARGO Therapeutics by 437.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 11,438 shares of the company’s stock valued at $211,000 after purchasing an additional 9,311 shares during the last quarter. SG Americas Securities LLC bought a new position in shares of CARGO Therapeutics during the 3rd quarter valued at $234,000. Finally, JPMorgan Chase & Co. grew its holdings in shares of CARGO Therapeutics by 74.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 15,007 shares of the company’s stock valued at $277,000 after purchasing an additional 6,426 shares during the last quarter. Institutional investors own 93.16% of the company’s stock.

CARGO Therapeutics Company Profile

CARGO Therapeutics, Inc, a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies.